Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Oxaliplatin +/- Cetuximab in First-Line Metastatic Colorectal Cancer
NCT00227734Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2004
- Primary completion
- Oct 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in colorectal cancer (CRC), sponsored by Swiss Group for Clinical Cancer Research. Started Jun 2004; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00227734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227734.